Literature DB >> 16884299

Brunsvicamides A-C: sponge-related cyanobacterial peptides with Mycobacterium tuberculosis protein tyrosine phosphatase inhibitory activity.

Daniela Müller1, Anja Krick, Stefan Kehraus, Christian Mehner, Mark Hart, Frithjof C Küpper, Krishna Saxena, Heino Prinz, Harald Schwalbe, Petra Janning, Herbert Waldmann, Gabriele M König.   

Abstract

The cyanobacterium Tychonema sp. produces the new cyclic hexapeptides brunsvicamide A-C (1-3). Brunsvicamide B (2) and C (3) selectively inhibit the Mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB), a potential drug target for tuberculosis therapy for which no inhibitors are known to date. Brunsvicamide C contains an N-methylated N'-formylkynurenine moiety, a unique structural motif in cyclic peptides. The new peptides are related to the sponge-derived mozamides, supporting the suggestion that secondary metabolites of certain marine invertebrates are produced by associated microorganisms. Thus, microorganisms phylogenetically related to symbionts of marine invertebrates can be judged as a means to supply "marine-like" compounds for drug development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16884299     DOI: 10.1021/jm060327w

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  20 in total

1.  Antimicrobial ambiguine isonitriles from the cyanobacterium Fischerella ambigua.

Authors:  Shunyan Mo; Aleksej Krunic; George Chlipala; Jimmy Orjala
Journal:  J Nat Prod       Date:  2009-05-22       Impact factor: 4.050

Review 2.  Chemodiversity in freshwater and terrestrial cyanobacteria - a source for drug discovery.

Authors:  George E Chlipala; Shunyan Mo; Jimmy Orjala
Journal:  Curr Drug Targets       Date:  2011-10       Impact factor: 3.465

Review 3.  Marine natural product peptides with therapeutic potential: Chemistry, biosynthesis, and pharmacology.

Authors:  Vedanjali Gogineni; Mark T Hamann
Journal:  Biochim Biophys Acta Gen Subj       Date:  2017-08-24       Impact factor: 3.770

4.  Lyngbyaureidamides A and B, two anabaenopeptins from the cultured freshwater cyanobacterium Lyngbya sp. (SAG 36.91).

Authors:  Jiachen Zi; Daniel D Lantvit; Steven M Swanson; Jimmy Orjala
Journal:  Phytochemistry       Date:  2011-12-05       Impact factor: 4.072

5.  Identification and characterization of novel inhibitors of mPTPB, an essential virulent phosphatase from Mycobacterium tuberculosis.

Authors:  Lan Chen; Bo Zhou; Sheng Zhang; Li Wu; Yuehong Wang; Scott G Franzblau; Zhong-Yin Zhang
Journal:  ACS Med Chem Lett       Date:  2010-10-14       Impact factor: 4.345

6.  Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents.

Authors:  Bo Zhou; Yantao He; Xian Zhang; Jie Xu; Yong Luo; Yuehong Wang; Scott G Franzblau; Zhenyun Yang; Rebecca J Chan; Yan Liu; Jianyu Zheng; Zhong-Yin Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-18       Impact factor: 11.205

Review 7.  Marine Cyclic Peptides: Antimicrobial Activity and Synthetic Strategies.

Authors:  Ricardo Ribeiro; Eugénia Pinto; Carla Fernandes; Emília Sousa
Journal:  Mar Drugs       Date:  2022-06-15       Impact factor: 6.085

8.  Total synthesis and antimicrobial activity of a natural cycloheptapeptide of marine origin.

Authors:  Rajiv Dahiya; Hemendra Gautam
Journal:  Mar Drugs       Date:  2010-08-19       Impact factor: 5.118

Review 9.  Marine pharmacology in 2005-6: Marine compounds with anthelmintic, antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action.

Authors:  Alejandro M S Mayer; Abimael D Rodríguez; Roberto G S Berlinck; Mark T Hamann
Journal:  Biochim Biophys Acta       Date:  2009-03-19

10.  Biosynthesis of the proteasome inhibitor syringolin A: the ureido group joining two amino acids originates from bicarbonate.

Authors:  Christina Ramel; Micha Tobler; Martin Meyer; Laurent Bigler; Marc-Olivier Ebert; Barbara Schellenberg; Robert Dudler
Journal:  BMC Biochem       Date:  2009-10-28       Impact factor: 4.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.